|
Jan 3
|
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
|
Jan 3
|
Neumora Stock Hits Record Low on Depression Drug Study Failure
|
|
Jan 2
|
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
|
|
Jan 2
|
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
|
|
Jul 25
|
CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?
|
|
Jul 22
|
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company
|
|
Jun 17
|
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
|
|
May 16
|
CytomX Therapeutics Announces New Employment Inducement Grants
|
|
May 9
|
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Q1 2024 CytomX Therapeutics Inc Earnings Call
|
|
May 9
|
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
|
|
May 8
|
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
|
|
May 2
|
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
|
|
May 1
|
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
|
|
Apr 25
|
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
|
|
Apr 8
|
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
|